Insights Into Hepatocellular Carcinoma (HCC)
Perspectives on drivers in treatment decisions in the management of HCC
Northeast – March 15, 2022
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center
Southwest – March 21, 2022
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center
Central – April 26, 2022
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center
Southwest #2 – May 17, 2022
Faculty Chair
Tanios Bekaii-Saab, MD
Mayo Clinic Cancer Center
Central #2 – September 26, 2022
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center
Mid-Atlantic – November 29, 2022
Faculty Chair
Daniel Ahn, DO
Mayo Clinic Cancer Center
More Information
- Philadelphia, PA
- Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Virtual series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual series
- Southwest
More Information
- Virtual series
- Puerto Rico
More Information
- Virtual series
- Denver, St. Louis, Kansas, Oklahoma
More Information
- Virtual series
- Midwest Region
More Information
- Virtual series
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Virtual series
- Baltimore, Philadelphia
REPORT SNAPSHOT
- A virtual, moderated roundtable discussion focusing on the treatment of HCC
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
